Intended for licensed healthcare professionals located in the United Kingdom only.

Stay Informed

shared.diamonds shared.diamonds

Sign up to receive updates from Incyte

Stay up to date with the latest news on PEMAZYRE®▼ (pemigatinib)

Please complete the form below to receive relevant information from Incyte, such as further information on PEMAZYRE and treatment of cholangiocarcinoma (CCA)

Fields marked with an * are mandatory.

Please check the boxes below before proceeding with submitting your information:


Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material on PEMAZYRE is available to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE

PEMAZYRE eDetail